262 related articles for article (PubMed ID: 32837853)
1. Colchicine in COVID-19: an Old Drug, New Use.
Schlesinger N; Firestein BL; Brunetti L
Curr Pharmacol Rep; 2020; 6(4):137-145. PubMed ID: 32837853
[TBL] [Abstract][Full Text] [Related]
2. Colchicine Against SARS-CoV-2 Infection: What is the Evidence?
Drosos AA; Pelechas E; Drossou V; Voulgari PV
Rheumatol Ther; 2022 Apr; 9(2):379-389. PubMed ID: 35107804
[TBL] [Abstract][Full Text] [Related]
3. Colchicine's effects on metabolic and inflammatory molecules in adults with obesity and metabolic syndrome: results from a pilot randomized controlled trial.
Demidowich AP; Levine JA; Apps R; Cheung FK; Chen J; Fantoni G; ; Patel TP; Yanovski JA
Int J Obes (Lond); 2020 Aug; 44(8):1793-1799. PubMed ID: 32461554
[TBL] [Abstract][Full Text] [Related]
4. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
5. A Review of the Rational and Current Evidence on Colchicine for COVID-19.
Ghaith HS; Gabra MD; Nafady MH; Elshawah HE; Negida A; Mushtaq G; Kamal MA
Curr Pharm Des; 2022; 28(39):3194-3201. PubMed ID: 34895117
[TBL] [Abstract][Full Text] [Related]
6. Repurposing colchicine's journey in view of drug-to-drug interactions. A review.
Vrachatis DA; Papathanasiou KA; Giotaki SG; Iliodromitis KE; Papaioannou TG; Stefanini GG; Cleman M; Siasos G; Reimers B; Lansky A; Tardif JC; Deftereos SG; Giannopoulos G
Toxicol Rep; 2021; 8():1389-1393. PubMed ID: 34285885
[TBL] [Abstract][Full Text] [Related]
7. Colchicine in the management of Covid-19: With or lieu of evidence.
Al-Kuraishy HM; Hussien NR; Al-Niemi MS; Al-Gareeb AI
J Pak Med Assoc; 2021 Dec; 71(Suppl 8)(12):S127-S132. PubMed ID: 35130235
[TBL] [Abstract][Full Text] [Related]
8. Colchicine use might be associated with lower mortality in COVID-19 patients: A meta-analysis.
Elshafei MN; El-Bardissy A; Khalil A; Danjuma M; Mubasher M; Abubeker IY; Mohamed MFH
Eur J Clin Invest; 2021 Sep; 51(9):e13645. PubMed ID: 34185313
[TBL] [Abstract][Full Text] [Related]
9. Colchicine and plaque: A focus on atherosclerosis imaging.
Aldana-Bitar J; Golub IS; Moore J; Krishnan S; Verghese D; Manubolu VS; Benzing T; Ichikawa K; Hamal S; Kianoush S; Anderson LR; Ramirez NR; Leipsic JA; Karlsberg RP; Budoff MJ
Prog Cardiovasc Dis; 2024; 84():68-75. PubMed ID: 38423236
[TBL] [Abstract][Full Text] [Related]
10. Colchicine's effects on lipoprotein particle concentrations in adults with metabolic syndrome: A secondary analysis of a randomized controlled trial.
Demidowich AP; Wolska A; Wilson SR; Levine JA; Sorokin AV; Brady SM; Remaley AT; Yanovski JA
J Clin Lipidol; 2019; 13(6):1016-1022.e2. PubMed ID: 31740368
[TBL] [Abstract][Full Text] [Related]
11. COVID-19 in patients with gout on colchicine.
Pelechas E; Drossou V; Voulgari PV; Drosos AA
Rheumatol Int; 2021 Aug; 41(8):1503-1507. PubMed ID: 34089357
[TBL] [Abstract][Full Text] [Related]
12. The impact of colchicine on patients with acute and chronic coronary artery disease.
Madanchi M; Young M; Tersalvi G; Maria Cioffi G; Attinger-Toller A; Cuculi F; Kurmann R; Bossard M
Eur J Intern Med; 2024 Jul; 125():1-9. PubMed ID: 38238134
[TBL] [Abstract][Full Text] [Related]
13. Colchicine in Gout: An Update.
Pascart T; Richette P
Curr Pharm Des; 2018; 24(6):684-689. PubMed ID: 29336252
[TBL] [Abstract][Full Text] [Related]
14. Proactive anti-inflammatory therapy with colchicine in the treatment of advanced stages of new coronavirus infection. The first results of the COLORIT study.
Mareev VY; Orlova YA; Plisyk AG; Pavlikova EP; Akopyan ZA; Matskeplishvili ST; Malakhov PS; Krasnova TN; Seredenina EM; Potapenko AV; Agapov MA; Asratyan DA; Dyachuk LI; Samokhodskaya LM; Mershina ЕА; Sinitsyn VE; Pakhomov PV; Zhdanova EA; Mareev YV; Begrambekova YL; Kamalov АА
Kardiologiia; 2021 Mar; 61(2):15-27. PubMed ID: 33734043
[TBL] [Abstract][Full Text] [Related]
15. Colchicine in Stable Coronary Artery Disease.
Fiolet ATL; Nidorf SM; Mosterd A; Cornel JH
Clin Ther; 2019 Jan; 41(1):30-40. PubMed ID: 30396516
[TBL] [Abstract][Full Text] [Related]
16. Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial.
Cuadrado-Lavín A; Olmos JM; Cifrian JM; Gimenez T; Gandarillas MA; García-Saiz M; Rebollo MH; Martínez-Taboada V; López-Hoyos M; Fariñas MC; Crespo J
Trials; 2020 Jun; 21(1):472. PubMed ID: 32493494
[TBL] [Abstract][Full Text] [Related]
17. Immunologic Dysregulation and Hypercoagulability as a Pathophysiologic Background in COVID-19 Infection and the Immunomodulating Role of Colchicine.
Vrachatis DA; Papathanasiou KA; Giotaki SG; Raisakis K; Kossyvakis C; Kaoukis A; Kolokathis F; Deftereos G; Iliodromitis KE; Avramides D; Bogossian H; Siasos G; Giannopoulos G; Reimers B; Lansky A; Tardif JC; Deftereos S
J Clin Med; 2021 Oct; 10(21):. PubMed ID: 34768648
[TBL] [Abstract][Full Text] [Related]
18. COVID-19: The Potential Role of Copper and N-acetylcysteine (NAC) in a Combination of Candidate Antiviral Treatments Against SARS-CoV-2.
Andreou A; Trantza S; Filippou D; Sipsas N; Tsiodras S
In Vivo; 2020 Jun; 34(3 Suppl):1567-1588. PubMed ID: 32503814
[TBL] [Abstract][Full Text] [Related]
19. Repurposing Colchicine in Treating Patients with COVID-19: A Systematic Review and Meta-Analysis.
Lien CH; Lee MD; Weng SL; Lin CH; Liu LY; Tai YL; Lei WT; Liu JM; Huang YN; Chi H; Chiu NC; Lin CY
Life (Basel); 2021 Aug; 11(8):. PubMed ID: 34440608
[TBL] [Abstract][Full Text] [Related]
20. Low-Dose Colchicine for the Prevention of Cardiovascular Events After Acute Coronary Syndrome.
Gera P; Wasserstein DH; Frishman WH; Aronow WS
Cardiol Rev; 2024 Jan; ():. PubMed ID: 38189365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
